Evidence map›Paper›PMID 22281797›Full record

ArticleChest2012

An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.

Raymond L Benza, Dave P Miller, Robyn J Barst, David B Badesch, Adaani E Frost, Michael D McGoon

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Chest, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 475 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
475citing papers in PubMed, 5 pooled it
60.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03617458 phase2completedstarted 2018, after this paper: background citation

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

Ran2018Enrolled73Registered outcomes39Posted comparisons0ConditionsPulmonary Artery HypertensionArmsMetformin, mHealth Intervention, Placebo, Usual Care
PMID 22723290PMID 1863023other papers from this trial
Open the trial in the graph
NCT05618093 nawithdrawnnot on this mapstarted 2023, after this paper: background citation

Use of Non-invasive Measurement of Cardiac Output and Stroke Volume to Assess Risk and Response to Treatment in Patients With PAH or CTEPH

TypeinterventionalSponsorUniversity of California, Los AngelesRan2023 to 2024Enrolled0ConditionsPulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary HypertensionArmsNon-invasive hemodynamic measurements
3 · Its place in the literature

Who cites it

475 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. The emerging role of integrin signaling in pulmonary vascular disease.American journal of physiology. Lung cellular and molecular physiology · 2026
    Review
  19. Observational
  20. Article

415 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Raymond L BenzaAllegheny General Hospital, Pittsburgh, PA. Electronic address: rbenza@wpahs.org.
Dave P MillerICON Late Phase and Outcomes Research, San Francisco, CA.
Robyn J BarstColumbia University College of Physicians and Surgeons, New York, NY.
David B BadeschUniversity of Colorado, Denver, CO.
Adaani E FrostBaylor College of Medicine, Houston, TX.
Michael D McGoonMayo Clinic, Rochester, MN.
Allegheny General Hospital · USBaylor College of Medicine · USColumbia University · USMayo Clinic · USUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL Registry) was established to characterize the clinical course, treatment, and predictors of outcomes in patients with pulmonary arterial hypertension (PAH) in the United States. To date, estimated survival based on time of patient enrollment has been established and reported. To determine whether the survival of patients with PAH has improved over recent decades, we assessed survival from time of diagnosis for the REVEAL Registry cohort and compared these results to the estimated survival using the National Institutes of Health (NIH) prognostic equation.

methodsNewly or previously diagnosed patients (aged ≥ 3 months at diagnosis) with PAH enrolled from March 2006 to December 2009 at 55 US centers were included in the current analysis.

resultsA total of 2,635 patients qualified for this analysis. One-, 3-, 5-, and 7-year survival rates from time of diagnostic right-sided heart catheterization were 85%, 68%, 57%, and 49%, respectively. For patients with idiopathic/familial PAH, survival rates were 91% ± 2%, 74% ± 2%, 65% ± 3%, and 59% ± 3% compared with estimated survival rates of 68%, 47%, 36%, and 32%, respectively, using the NIH equation.

conclusionsComprehensive analysis of survival from time of diagnosis in a large cohort of patients with PAH suggests considerable improvements in survival in the past 2 decades since the establishment of the NIH registry, the effects of which most likely reflect a combination of changes in treatments, improved patient support strategies, and possibly a PAH population at variance with other cohorts

Indexed as

Disease ManagementRegistriesAdultAgedCardiac CatheterizationCohort StudiesFamilial Primary Pulmonary HypertensionFemaleHumansHypertension, PulmonaryMaleMiddle AgedPrognosisSurvival RateUnited StatesYoung Adult

Identifiers

PMID22281797
OpenAlexW2140319297

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.